FPR2: A Potential Drug Target for Multiple Myeloma (G2358)

Target Name: FPR2

NCBI ID: G2358

FPR2

FPR2: A Potential Drug Target for Multiple Myeloma

FPR2 (Alx) is a protein that is expressed in the plasma cells of individuals with multiple myeloma, a type of cancer that affects the bone marrow. It is a protein that is known to play a role in the development and progression of this disease.

Recent studies have suggested that FPR2 may be a potential drug target or biomarker for multiple myeloma. This has led to a significant amount of interest in this protein and its potential uses in cancer treatment.

Understanding FPR2

FPR2 is a single-chain protein that is expressed in the plasma cells of multiple myeloma. It is made up of 254 amino acids and has a calculated molecular mass of 31.1 kDa. FPR2 is found in the extracellular space and can be easily purified from plasma samples using techniques such as affinity chromatography.

The Role of FPR2 in Multiple Myeloma

Multiple myeloma is a type of cancer that affects the bone marrow. It is characterized by the production of a single clone of abnormal white blood cells called a pl clone. In multiple myeloma, the pl clone of cells grows out of control and can cause a variety of symptoms, including bone pain, fatigue, and anemia.

FPR2 has been shown to play a role in the development and progression of multiple myeloma. Studies have shown that FPR2 is highly expressed in the plasma cells of individuals with multiple myeloma and that it is associated with poor prognosis in these individuals.

FPR2 also has been shown to promote the growth and survival of multiple myeloma cells. This has led to the hypothesis that FPR2 may be a potential drug target or biomarker for this disease.

Potential Therapies

Given the interest in FPR2 as a potential drug target or biomarker for multiple myeloma, there are currently several research studies being conducted to investigate its potential uses in cancer treatment.

One of the most promising approaches is the use of antibodies to target FPR2 directly. Studies have shown that antibodies directed against FPR2 can effectively inhibit the growth and survival of multiple myeloma cells.

Another approach being explored is the use of small molecules to inhibit the activity of FPR2. This approach has been shown to be effective in inhibiting the growth and survival of multiple myeloma cells.

Another approach is the use of drugs that can inhibit the activity of FPR2 and its downstream targets. Studies have shown that inhibitors of FPR2 such as aloe saponin and API2-128 can effectively inhibit the growth and survival of multiple myeloma cells.

Conclusion

FPR2 is a protein that has been shown to play a role in the development and progression of multiple myeloma. Its high expression and association with poor prognosis make it a promising target for cancer treatment. Studies have shown that antibodies and small molecules can be effective in inhibiting the activity of FPR2 and its downstream targets. Further research is needed to fully understand the potential uses of FPR2 as a drug target or biomarker for multiple myeloma.

Protein Name: Formyl Peptide Receptor 2

Functions: Low affinity receptor for N-formyl-methionyl peptides, which are powerful neutrophil chemotactic factors (PubMed:1374236). Binding of FMLP to the receptor causes activation of neutrophils (PubMed:1374236). This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system (PubMed:1374236). The activation of LXA4R could result in an anti-inflammatory outcome counteracting the actions of pro-inflammatory signals such as LTB4 (leukotriene B4) (PubMed:9547339). Receptor for the chemokine-like protein FAM19A5, mediating FAM19A5-stimulated macrophage chemotaxis and the inhibitory effect on TNFSF11/RANKL-induced osteoclast differentiation (By similarity). Acts as a receptor for humanin (PubMed:15465011)

The "FPR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FPR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets